• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Adherium

Adherium inks digital health deal with Summatix

August 21, 2019 By Sean Whooley

adherium

Adherium (ASX:ADR) announced a data-based initiative with Summatix to allow clinicians to improve care of patients with asthma and chronic obstructive pulmonary disease across the world. New Zealand-based Adherium and Australia-based Summatix plan to build upon an existing relationship, as the former will gain access to Summatix’s platform to release data from its Hailie sensors […]

Filed Under: Featured, Mergers & Acquisitions, mHealth (Mobile Health), Respiratory Tagged With: Adherium, Summatix

Adherium launches over-the-counter inhaler sensor in US

August 13, 2018 By Sarah Faulkner

 Adherium (ASK:ADR) today launched over-the-counter sales of its Hailie digital inhaler add-on in the U.S. The sensor is designed to integrate directly with prescription inhaler medications, sending adherence reminders and relevant data to a user’s smartphone to assist in managing chronic respiratory conditions like asthma and COPD. “We’re extremely excited to announce the availability of the […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Adherium

Adherium looks to give doctors a window into their patients’ lives

May 30, 2018 By Sarah Faulkner

To control an asthma patient’s symptoms, doctors will prescribe an inhaler to stop symptoms from cropping up and a rescue inhaler to be used if patients find themselves in the middle of an asthma attack. “But if your rescue inhaler doesn’t give you the relief that you need, your next recourse is to go to […]

Filed Under: Big Data, Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory Tagged With: Adherium, AstraZeneca plc

FDA clears Adherium’s inhaler sensor for OTC sales

April 3, 2018 By Sarah Faulkner

The FDA gave Adherium (ASK:ADR) the go-ahead to launch over-the-counter sales of its Smartinhaler sensor for AstraZeneca‘s (NYSE:AZN) Symbicort asthma inhaler, the company touted last week. Adherium’s product installs directly onto a patient’s inhaler to monitor and boost medication adherence. The device records the time and date that a patient uses their inhaler and transmits […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Adherium, AstraZeneca plc

Adherium to expand in U.S. market with direct-to-consumer push for smart inhaler tech

January 25, 2018 By Sarah Faulkner

adherium

Adherium Ltd. (ASK:ADR), which sells a smart inhaler technology in Europe and Australia, is reportedly looking to jump into the direct-to-consumer U.S. market in the first half of this year. The New Zealand-based company has a deal with AstraZeneca (NYSE:AZN) to combine its Smartinhaler monitoring device with the Symbicort inhaler, but CEO Arik Anderson told MobiHealthNews that he is […]

Filed Under: Drug-Device Combinations, Featured, Patient Monitoring, Pharmaceuticals, Respiratory Tagged With: Adherium

Adherium launches next-gen monitor for AstraZeneca’s Turbuhaler

September 13, 2017 By Sarah Faulkner

Adherium Ltd. (ASK:ADR) said today that it launched a next-gen version of its SmartTurbo adherence monitor for AstraZeneca‘s (NYSE:AZN) Turbuhaler. The company’s monitor features usability improvements to make the device’s installation and removal easier for older patients with COPD. It also includes larger buttons to help patients access features like audio and visual reminders, battery monitoring […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Adherium, AstraZeneca plc

Adherium wins 510(k) clearance for smart inhaler monitoring device

September 1, 2017 By Sarah Faulkner

adherium

Adherium Ltd. (ASK:ADR) said today that it won 510(k) approval from the FDA for its inhaler monitoring device, SmartTouch for Symbicort. The device was cleared for use with AstraZeneca‘s (NYSE:AZN) Symbicort aerosol inhaler. The Melbourne, Australia-based company’s product installs directly onto a patient’s inhaler to monitor and boost medication adherence. The device records the time and […]

Filed Under: Drug-Device Combinations, Featured, Food & Drug Administration (FDA), Pharmaceuticals, Regulatory/Compliance, Respiratory, Wall Street Beat Tagged With: Adherium, AstraZeneca plc

Collecting purposeful data in the era of connected health devices

February 16, 2017 By Sarah Faulkner

Collecting purposeful data in the era of connected health devices

Connectivity, one of the newest buzzwords in the medical device lexicon, is becoming more and more integral to device design and development. Research shows that connected health devices can improve patient outcomes by increasing adherence and reducing dosing variability. Mark David Tuckwell, head of electronics, software & systems at Sagentia, says connected device can also provide crucial information to help […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: Adherium, Baxter International, Becton Dickinson, Companion Medical, GlaxoSmithKline plc, Propeller Health, Sagentia, Sanofi-Aventis

Adherium’s smart inhaler tech chosen for EU mobile health program

December 12, 2016 By Sarah Faulkner

adherium

Adherium Ltd. (ASK:ADR) said today that its Smartinhaler was chosen for the myAirCoach program as a part of the European Union’s Horizon 2020 Framework for Research and Innovation. The Horizon 2020 program is the largest EU research and innovation program ever established, with €80 billion (nearly $85 billion) of funding available from 2014 until 2020. The […]

Filed Under: Drug-Device Combinations, Featured, mHealth (Mobile Health), Pharmaceuticals, Respiratory, Wall Street Beat Tagged With: Adherium, AstraZeneca plc, GlaxoSmithKline plc

Adherium touts Smartinhaler asthma study

November 17, 2016 By Sarah Faulkner

adherium

Adherium (ASK:ADR) touted data from an independent study of its Smartinhaler respiratory disease management tool in children with poorly controlled asthma. The STAAR study was conducted at Sheffield Children’s Hospital in the UK and the results were published this month in Thorax.  The New Zealand-based company found that in children with poorly controlled asthma, introducing its […]

Filed Under: Clinical Trials, Featured, Patient Monitoring, Research & Development, Respiratory Tagged With: Adherium

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS